SCHEMBL23212216

SCHEMBL23212216

CCOC(=O)c1[nH]cc2c(=O)n(C)cc(Br)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRB2 P47870 1/20 0.38
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
MAPT P10636 3/20 0.37
PKM P14618 2/20 0.37
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 1/20 0.36
TNF P01375 1/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28635546 0.82 BRD4 (0.34) L3MBTL1BRD4
SCHEMBL17974952 0.77 CLEC4M (0.47) GABRA1GABRB1GABRA3GABRB2BAZ2B
SCHEMBL22460764 0.73 BRD4 (0.48) BAZ2BBAZ2AMAPTPKMALDH1A1
SCHEMBL17963447 0.71 MAPT (0.45) MAPTPKMALDH1A1GAAHPGD
SCHEMBL9486423 0.70 KDM4E (0.45) GABRA1GABRB1GABRA3GABRB2MAPT
SCHEMBL16115982 0.70 CYP1A2 (0.49) MAPTPKMALDH1A1HPGDKDM4E
SCHEMBL21904793 0.70 TSHR (0.57) BAZ2BBAZ2AMAPTPKMALDH1A1
SCHEMBL15956965 0.70 BRD4 (0.53) BAZ2BBAZ2AMAPTPKMALDH1A1
SCHEMBL27817639 0.70 CLEC4M (0.47) GABRA1GABRB1GABRA3GABRB2MAPT
SCHEMBL27932262 0.69 CYP1A2 (0.44) GABRA1GABRB1GABRA3GABRB2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114401964-B Compound with BRD4 inhibitory activity, preparation method and application thereof 上海海和药物研究开发股份有限公司 2024-10-01 CN disclosed
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2024-05-09 US disclosed
EP-4043462-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF Haihe Biopharma Co., Ltd. (CN) 2022-08-17 EP disclosed
CN-114401964-A Compound with BRD4 inhibitory activity, preparation method and application thereof 上海海和药物研究开发股份有限公司 2022-04-26 CN disclosed
WO-2021068755-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF 上海海和药物研究开发股份有限公司 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF BRD4, BICRA, BET1 GABRA1 1036/4885GABRB1 908/4885GABRA3 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.